Rice Hall James & Associates LLC Sells 35,684 Shares of LeMaitre Vascular, Inc. $LMAT

Rice Hall James & Associates LLC lowered its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 16.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 178,186 shares of the medical instruments supplier’s stock after selling 35,684 shares during the quarter. Rice Hall James & Associates LLC’s holdings in LeMaitre Vascular were worth $15,593,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Parkside Financial Bank & Trust grew its stake in LeMaitre Vascular by 1,913.3% during the second quarter. Parkside Financial Bank & Trust now owns 302 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 287 shares during the period. Geneos Wealth Management Inc. boosted its holdings in shares of LeMaitre Vascular by 250.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after buying an additional 398 shares in the last quarter. EverSource Wealth Advisors LLC acquired a new stake in shares of LeMaitre Vascular during the 2nd quarter worth approximately $47,000. Laurel Wealth Advisors LLC increased its stake in shares of LeMaitre Vascular by 8,205.6% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 1,495 shares of the medical instruments supplier’s stock valued at $124,000 after acquiring an additional 1,477 shares in the last quarter. Finally, Pacer Advisors Inc. lifted its position in shares of LeMaitre Vascular by 48.4% during the 3rd quarter. Pacer Advisors Inc. now owns 1,659 shares of the medical instruments supplier’s stock valued at $145,000 after acquiring an additional 541 shares during the period. 84.64% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

LMAT has been the subject of a number of research reports. Weiss Ratings restated a “buy (b-)” rating on shares of LeMaitre Vascular in a report on Monday. Wall Street Zen downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday, December 6th. Wells Fargo & Company decreased their target price on LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating for the company in a research report on Friday, November 7th. Zacks Research raised LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 7th. Finally, Barrington Research reaffirmed an “outperform” rating and set a $95.00 target price on shares of LeMaitre Vascular in a research report on Wednesday, October 15th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $100.20.

LeMaitre Vascular Stock Performance

Shares of LMAT opened at $83.78 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 11.45 and a current ratio of 13.58. The stock has a 50 day moving average price of $86.00 and a two-hundred day moving average price of $87.25. The firm has a market capitalization of $1.90 billion, a P/E ratio of 36.11, a P/E/G ratio of 2.09 and a beta of 0.68. LeMaitre Vascular, Inc. has a 52 week low of $71.42 and a 52 week high of $105.55.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, November 6th. The medical instruments supplier reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.57 by $0.05. LeMaitre Vascular had a return on equity of 14.06% and a net margin of 22.14%.The company had revenue of $61.05 million for the quarter, compared to analyst estimates of $62.18 million. During the same quarter last year, the company earned $0.49 earnings per share. The company’s revenue for the quarter was up 11.4% on a year-over-year basis. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS and its Q4 2025 guidance at 0.640-0.690 EPS. Equities analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, December 4th. Stockholders of record on Thursday, November 20th were paid a $0.20 dividend. The ex-dividend date was Thursday, November 20th. This represents a $0.80 annualized dividend and a dividend yield of 1.0%. LeMaitre Vascular’s dividend payout ratio is presently 34.48%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.